All News

gout.MTP_.jpg

Decreasing immunogenicity, improving efficacy of pegloticase in gout

Bella Mehta, MBBS, MS

At #ACR20 three different medications are reviewed in different studies to decrease the immunogenicity of pegloticase – Methotrexate, Azathioprine and Mycophenolate Mofetil.  

Read Article
gout.podagra.jpg

Mitigating Immunogenicity When Using Uricase Therapies as ULT

Alexa Meara MD

ACR20 convergence highlights a shift in gout management and uric acid lowering therapy (ULT). The new biologics pegdriticase and pegloticase are associated with risk of immunogenicity and loss of biological effects.

Read Article
EULAR19.abstract.jpg (keep)

ACR Best Abstracts - Day 1

Jack Cush, MD

The RheumNow faculty reporters have been glued to their monitors all day, viewing video, reading and listening to abstract presentations and I charged them to earmark those presentations were the “Best” they saw today. Below is the list of most often noted #ACRbest abstracts from Day 1.

Read Article
ACRmtg.jpg (keep)

Industry Abstract Previews - ACR2020

Jack Cush, MD

Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020.  This is our selection of their best studies for you to review and evaluate as part of your to-do list.

Read Article
Evidence-Based Guidance for Optimizing Gout #ACR20 Reminding us of cardioprotective effect of anti-inflammatory gout management with colchicine. https://t.co/TmsrRd2vFD
Jilaine Bolek Berquist BolekBerqui ( View Tweet)
Is diet important in gout control? #ACR20 @rheumnow

Richard Conway RichardPAConway ( View Tweet)

@RheumNow #acr20 abs0665 claim based database stdy of pegloticase/immunomodulation coadministration trends: use of co-immunomodulation ⬆️ from 1.2%-3.9% 2015- 2018 to 15.0% in 2019. 86%start immunomodulator within 30 days of first peg infusion. MTX most commonly used

Olga Petryna DrPetryna ( View Tweet)

@RheumNow #acr20 abs0690 ph2a trial: potent reduction of sUA w/URAT1 inhibitor AA882. 100% of pts sUA levels < 6 mg/dL &63% pts < 5 mg/dL compared to febuxostat 50% & 13% respectively. Even more remarkable reduction w/ AA882+febuxostat. Mild to moderate SEs. https://t.co/XrDJXEoC1j
Olga Petryna DrPetryna ( View Tweet)
@RheumNow #acr20 abs0600 a case control stdy of 545 CHF exacerbate admissions: pts w/gout flares median LoS 10 d vs 6 d w/out flare or gout at all. log LoS w gout flare 2.41 ± 0.96 vs 1.77 ± 0.90 w/out, p < 0.0001. Prevention of gout flares in CHF pts of essence #ACRbest https://t.co/8xiHHYxvsC
Olga Petryna DrPetryna ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow and its Faculty.

Dr. John Cush RheumNow ( View Tweet)

@RheumNow #acr20 abs 0649 PROTECT trial of pegloticase in 7 kidney transplant pts w/uncontrolled gout: 2-12 infusions, 2+immunosuppressants on board for transplant care. No change in eGFR, HAQ pain ⬇️by 33.8 at wk20. Alb/cr improved by >35%in 2pts. sUA< 1 mg/dL, no serious AEs https://t.co/f4tnFjMTe8
Olga Petryna DrPetryna ( View Tweet)
How often, if ever, do you use DECT to diagnose gout?

Olga Petryna DrPetryna ( View Tweet)

Dr Peral reports on intracellular crystal containing vacuoles in gout and CPP arthritis. Crystal containing vacuoles only seen in CPP arthritis. @rheumnow #ACR20 Abstr#666 https://t.co/ITQMXhjQt0
Richard Conway RichardPAConway ( View Tweet)
Dr Vargas-Santos reported on risk of gout with SGLT2-inhibitors using THIN database. Canagliflozin shown in prior RCT to reduce gout risk. Here dapagliflozin and empagliflozin showed even stronger effect @rheumnow #ACR20 Abstr#660 https://t.co/MTjByMmHo7
Richard Conway RichardPAConway ( View Tweet)
Dr Minalyan and colleagues report rates of gout flare following hospital admission of patients prescribed allopurinol. Gout flare 14 times more likely if allopurinol stopped or omitted. @rheumnow #ACR20 Abstr#688 https://t.co/x3eyX1PLFB
Richard Conway RichardPAConway ( View Tweet)
Dr McCormick reports sequential patterns of gout flare from the Boston Online Gout Study. Second attack most likely to affect ipsilateral same joint, and second most likely contralateral same joint. @rheumnow #ACR20 Abstr#672 https://t.co/2AAMvcOCk8
Richard Conway RichardPAConway ( View Tweet)
Get the highlights on the opening day of #ACR20. Listen in to faculty reports and overviews. Follow the link below or find us on Apple podcasts under RheumNow Podcast. https://t.co/qDQzCAHsHi https://t.co/9nM19ZdHQQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr Murdoch and colleagues report “An Apple Pie a Day Does Not Keep the Doctor Away”. An analysis of the negative depictions of gout in tv and film and how this may affect our care. @rheumnow #ACR20 Abstr#646 https://t.co/BBW0Fd5kHE
Richard Conway RichardPAConway ( View Tweet)
DECT in #gout: color-coded lesions at MTP1 jt & patellar tendon exclusively pure MSU depositions. CCDL in gout: both pure MSU & calcium-containing depositios. @RheumNow #ACR20 Abs#0445 https://t.co/7zudk2muBR
sheila RHEUMarampa ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by BMS, @HorizonNews , @SanofiGenzyme, @Novartis. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×